Omega Diagnostics Group PLC – ODX – Directorate Change

Omega Diagnostics Group PLC – ODX – Directorate Change

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate effect, after a thorough search process that was conducted with the help of Snedden Campbell Ltd. Simon has also become a member of both the Audit Committee and the Remuneration Committee.

 

Simon has 25 years of Board level experience at both early stage and public businesses within the Diagnostics, Life Science and BioPharma industries. Simon is currently Non-Executive Chairman at AIM listed Fusion Antibodies plc, having previously served as its Chief Executive Officer up until 2011. Simon is also Non-Executive Chairman of C-Major Medical, a private limited company. Simon holds a PhD in in-vivo Diagnostics and an MPhil in Immunology, both from the University of Southampton.

 

As a result of the appointment, Bill Rhodes has stepped down from his position as Interim Non-Executive Chairman with immediate effect, but he remains as a Non-Executive Director of the Company.

 

Bill Rhodes said: 

"It has been my honour to serve as Interim Chairman for nearly three years now.  We have seen Omega gain significant momentum recently as the need for accurate lateral flow diagnostic tests has increased, and I believe Simon is the right individual to support the Company in gaining even greater levels of success."

 

Colin King, Chief Executive Officer said: 

"We very much welcome Simon to the board and look forward to working with him and benefiting from his wide experience.   We thank Bill for all his work as our Interim Chairman and look forward to his ongoing contribution as part of our expanded Board."

 

Simon Douglas, Chairman said:

"I am delighted to be joining Omega at such an exciting time in their development and growth. I look forward to contributing to the continued growth of their core businesses in infectious disease with their lateral flow CD4 and Covid products, together with their Food Intolerance business, a market leader in this sector, both of which have an exciting future."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

The following information is disclosed about Dr. Simon Gordon Douglas, age 62pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Current Directorships / Partnerships:

 

Fusion Antibodies plc

C-Major Limited (since September 2019)

 

Previous Directorships / Partnerships (held in the past five years)

 

Biofortuna Ltd

C-Major Limited (September 2014 until May 2017)

 

Dr. Douglas does not currently hold any ordinary shares in the Company.  There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

No Comments

Post a Comment